Susceptibility Studies of Novel Antimicrobial Drugs Against Carbapenem‐Resistant and Hypervirulent Klebsiella pneumoniae

抗菌剂 医学 抗生素 抗感染药 免疫系统 药品 生物 药物开发 药理学 传统医学
作者
Yi Li,Xiao Wang,Jie Yang,Yulian Li,Xun Jia,Huinan Mao,Dan Li,Jie Zhang
出处
期刊:Journal of Evidence-based Medicine [Wiley]
卷期号:19 (2): e70113-e70113
标识
DOI:10.1111/jebm.70113
摘要

ABSTRACT Background Carbapenem‐resistant hypervirulent Klebsiella pneumoniae (CR‐hvKp) is a growing concern due to high mortality and limited therapies, with scarce data on novel antimicrobials in vitro activity against it. Aims This research evaluated the in vitro efficacy of six novel antimicrobial drugs including ceftolozane/tazobactam, cefiderocol, eravacycline, omadacycline, temocillin, and plazomicin, against CR‐hvKP and characterize its molecular epidemiology. Methods 106 non‐repetitive clinical CR‐hvKP strains were collected from Sichuan Provincial People's Hospital between August 2018 and December 2023. CR‐hvKP were identified using VITEK‐2 Compact and MALDI‐TOF MS, confirmed via string tests and PCR. The E‐test strip method assessed the in vitro antibacterial activity of novel antimicrobial drugs against CR‐hvKP. The molecular characterization of CR‐hvKP was conducted by PCR to amplify resistance genes, virulence genes, housekeeping genes, and wzi genes. The Galleria mellonella infection model explored the virulence characteristics of CR‐hvKP strains. Results CR‐hvKP had a relatively high susceptibility rate of 96.2% to cefiderocol, showing good antibacterial activity, whereas ceftolozane/tazobactam, temocillin, omadacycline, eravacycline, and plazomicin exhibited high resistance rates (81.1%–99.1%). ST11‐KL64 was the predominant type in CR‐hvKP strains. We identified three new ST subtypes, ST8115, ST8116 and ST8117. The most prevalent carbapenemase genes were bla KPC and bla NDM , and approximately 75.5% of CR‐hvKP carried bla KPC , bla SHV , and bl a CTX‐M . Conclusions Cefiderocol appears highly promising as a therapy for CR‐hvKP infections. Our findings will not only effectively address the challenge of CR‐hvKP resistance, but also provide evidence to support the optimization of clinical therapeutic strategies and further promote the development and application of novel antimicrobial drugs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
邱邱邱完成签到,获得积分10
1秒前
1秒前
1秒前
vv发布了新的文献求助10
2秒前
3秒前
wy发布了新的文献求助10
3秒前
ubless607发布了新的文献求助10
4秒前
聪慧雁凡完成签到,获得积分10
4秒前
幽默枫完成签到,获得积分10
4秒前
4秒前
5秒前
饱满一刀完成签到,获得积分10
5秒前
科研通AI65的应助被zbw采纳,获得10
5秒前
嘎嘣脆发布了新的文献求助10
5秒前
mingjuan完成签到 ,获得积分10
6秒前
CodeCraft的应助被ddw采纳,获得10
6秒前
白云千载完成签到,获得积分10
7秒前
蓝蓝纸啊完成签到 ,获得积分10
7秒前
Lucifer发布了新的文献求助10
7秒前
淡淡的铭完成签到,获得积分20
9秒前
ni完成签到 ,获得积分10
10秒前
EgbertW完成签到,获得积分0
10秒前
彭彭完成签到,获得积分10
11秒前
kori的应助被H欢采纳,获得10
12秒前
西瓜皮完成签到 ,获得积分10
12秒前
12秒前
12秒前
小二郎的应助被sdyxz采纳,获得10
13秒前
14秒前
14秒前
思源的应助被Andy采纳,获得10
15秒前
ZQ完成签到,获得积分10
15秒前
15秒前
15秒前
wyd222完成签到,获得积分10
15秒前
16秒前
minbio完成签到,获得积分10
16秒前
科研通AI6.3的应助被Apricity采纳,获得10
16秒前
Zth发布了新的文献求助10
16秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187592
求助须知:如何正确求助?哪些是违规求助? 9575705
关于积分的说明 21842471
捐赠科研通 7785407
什么是DOI,文献DOI怎么找? 3435057
关于科研通互助平台的介绍 2559461
邀请新用户注册赠送积分活动 2481952